New Alzheimer's drug slightly slows cognitive decline. Experts say it's not a silver bullet.
Jan 20 2023
Experts, including Stanford researchers, weigh in on whether the newly approved Alzheimer's treatment lecanemab is worth taking.
Experts, including Stanford researchers, weigh in on whether the newly approved Alzheimer's treatment lecanemab is worth taking.
